Scalper1 News
Regeneron Pharmaceuticals (REGN) rebounded more than 6% in afternoon trading on the stock market today when development partner Sanofi (SNY) said in a U.S. regulatory filing that it will raise its stake from 20.44% to 22.5%. The French drug giant’s move comes after Regeneron superstar Eylea, a treatment for age-related macular degeneration (AMD), received a European Medicines Agency endorsement on Friday to expand its use to other types of vision Scalper1 News
Scalper1 News